1st Quarter - Report

BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ for PLASMA PROTEIN THERAPEUTICS ASSOCIATION

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$30,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 19, 2016 $30,000 Replaced
1st Quarter - Termination Jan 26, 2017 $30,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare reimbursement relating to plasma protein therapies; H.R. 2581, Preservation of Access for Seniors in Medicare Advantage Act of 2015, and H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors of 2015, provisions related to DME infused drugs; H.R. 6, 21st Century Cures Act, provisions related to DME infusion drugs. Medicare reimbursement methodology for DME infused drugs, generally.

LobbyistCovered position, as disclosed
NICOLE CARELLI —
SARA LOVE RAWLINGS New Senate Appropriations Committee
CAROLINE SELBY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 6 (114th), H.R. 2570 (114th), H.R. 2581 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.